Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of care fragmentation in patients receiving neoadjuvant chemotherapy and radical cystectomy for bladder cancer.
Authors
Carlos Riveros
University of Florida, Jacksonville, FL
Carlos Riveros , Victor Chalfant , KC Balaji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 468)
DOI
10.1200/JCO.2022.40.6_suppl.468
Abstract #
468
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
First Author: Leilei Xia
Poster
2024 ASCO Genitourinary Cancers Symposium
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
First Author: Ryan Michael Antar
Poster
2023 ASCO Genitourinary Cancers Symposium
The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
First Author: Jonathan Thomas